SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Ossenkoppele Gert)
 

Sökning: WFRF:(Ossenkoppele Gert) > (2013) > Plerixafor and gran...

  • Russell, Nigel (författare)

Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma : results of the prospective PREDICT trial

  • Artikel/kapitelEngelska2013

Förlag, utgivningsår, omfång ...

  • 2012-09-14
  • Ferrata Storti Foundation (Haematologica),2013
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:uu-189691
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-189691URI
  • https://doi.org/10.3324/haematol.2012.071456DOI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • In Europe, the combination of plerixafor + granulocyte colony-stimulating factor is approved for the mobilization of hematopoietic stem cells for autologous transplantation in patients with lymphoma and myeloma whose cells mobilize poorly. The purpose of this study was to further assess the safety and efficacy of plerixafor + granulocyte colony-stimulating factor for front-line mobilization in European patients with lymphoma or myeloma. In this multicenter, open label, single-arm study, patients received granulocyte colony-stimulating factor (10 μg/kg/day) subcutaneously for 4 days; on the evening of day 4 they were given plerixafor (0.24 mg/kg) subcutaneously. Patients underwent apheresis on day 5 after a morning dose of granulocyte colony-stimulating factor. The primary study objective was to confirm the safety of mobilization with plerixafor. Secondary objectives included assessment of efficacy (apheresis yield, time to engraftment). The combination of plerixafor + granulocyte colony-stimulating factor was used to mobilize hematopoietic stem cells in 118 patients (90 with myeloma, 25 with non-Hodgkin's lymphoma, 3 with Hodgkin's disease). Treatment-emergent plerixafor-related adverse events were reported in 24 patients. Most adverse events occurred within 1 hour after injection, were grade 1 or 2 in severity and included gastrointestinal disorders or injection-site reactions. The minimum cell yield (≥2×106 CD34+ cells/kg) was harvested in 98% of patients with myeloma and in 80% of those with non-Hodgkin's lymphoma in a median of one apheresis. The optimum cell dose (≥5×106 CD34+ cells/kg for non-Hodgkin's lymphoma or ≥6×106 CD34+ cells/kg for myeloma) was harvested in 89% of myeloma patients and 48% of non-Hodgkin's lymphoma patients. In this prospective, multicenter European study, mobilization with plerixafor + granulocyte colony-stimulating factor allowed the majority of patients with myeloma or non-Hodgkin's lymphoma to undergo transplantation with minimal toxicity, providing further data supporting the safety and efficacy of plerixafor + granulocyte colony-stimulating factor for front-line mobilization of hematopoietic stem cells in patients with non-Hodgkin's lymphoma or myeloma.

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Douglas, Kenny (författare)
  • Ho, Anthony (författare)
  • Mohty, Mohamad (författare)
  • Carlson, KristinaUppsala universitet,Hematologi(Swepub:uu)krica965 (författare)
  • Ossenkoppele, Gert J (författare)
  • Milone, Giuseppe (författare)
  • Pareja, Macarena Ortiz (författare)
  • Shaheen, Daniel J (författare)
  • Willemsen, Arnold (författare)
  • Whitaker, Nicky (författare)
  • Chabannon, Christian (författare)
  • Uppsala universitetHematologi (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Haematologica: Ferrata Storti Foundation (Haematologica)98:2, s. 172-1780390-60781592-8721

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy